PANTHERx Rare appoints new CEO

Pittsburgh-based PANTHERx Rare, a specialty pharmacy purely focused on rare and orphan diseases, recently named Bansi Nagji CEO, effective Aug. 1.

Nagji is currently executive chairman, and he will continue to hold his seat on the board of directors. The executive chairman is responsible for working with industry partners to ensure PANTHERx Rare maintains its reputation for providing patient access to essential medications.

In his new role, Nagji will be responsible for a variety of clinical, operational, and business development initiatives.

He has more than 25 years of leadership experience in digital platforms, healthcare technology, and pharma services and supply chain. Prior to joining PANTHERx Rare, he served as GoodRx president of healthcare, and McKesson Corp. executive vice president and chief strategy and business development officer. He has served on the boards of directors for private and public companies including Change Healthcare.

Nagji replaces Rob Snyder who will become full-time executive chairman. Snyder co-founded the company in 2011 and has helped lead it through a period of growth and transformation.

PANTHERx Rare is a dual-accredited specialty pharmacy holding distinctions in rare disease including the Accreditation Commission for Health Care Distinction in Orphan Drugs and Utilization Review Accreditation Commission Rare Disease Center of Excellence.

The post PANTHERx Rare appoints new CEO appeared first on Pennsylvania Business Report .